Overview

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
Phase:
N/A
Details
Lead Sponsor:
Kentuckiana Cancer Institute
Treatments:
Gemcitabine